(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
NASA begins fueling rocket to launch astronauts on the first lunar trip in half a century - 2The Most Enrapturing Authentic Milestones to Visit
- 3How to track NASA’s Artemis II and Orion’s journey to the moon
- 4How a toxic self-improvement trend with a funny name took over your feed
- 5Flourishing in a Cutthroat Work Market: Vocation Methodologies
- Step by step instructions to Explore Assessment Ramifications of Disc Rates
- Flu cases are spiking earlier than usual. What you need to know.
- The Best Traditional Music Arrangers in History
- Geminid meteors streak under green sky | Space photo of the day for Dec. 19, 2025
- 6 Exemplary Mexican Dishes
- Israel says 40 Hezbollah members killed as forces advance in Lebanon
- Shrewd Home Gadgets to Save Energy
- Eating ultra-processed foods could raise precancerous polyp risk for women under 50, according to research
- Early Thanksgiving week forecast: Where Americans can expect cold, rain and snow for the holiday
